A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. (NCT07042100)
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Who can join: Review the eligibility criteria below.
Location: Honorhealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Honorhealth Research Institute — Scottsdale, Arizona
- Sarcoma Oncology Research Center — Santa Monica, California
- Yale University - Yale Cancer Center — New Haven, Connecticut
- Hope and Healing Clinical Research LLC — Hinsdale, Illinois
- MD Anderson Cancer Center — Houston, Texas
- Scientia Clinical Research — Randwick, New South Wales
- Sunshine Coast University Private Hospital — Birtinya, Queensland
- Cancer Research South Australia — Adelaide, South Australia
- Kainos Super Speciality Hopsital — Rohtak, Haryana
- Amrita Institute of Medical Sciences — Ernākulam, Kerala
- Sir H.N Reliance Foundation Hospital — Mumbai, Maharashtra
- Tata Memorial hospital — Mumbai, Maharashtra
- Noble Hospital Pvt. Ltd. — Pune, Maharashtra
- All India Institute for Medical Sciences — Delhi, New Delhi
- S.P. Medical College and AG of Hospitals — Bikaner, Rajasthan
- Pacific Medical College and Hospital — Udaipur, Rajasthan
📞 Contact the Study Coordinator
Phone: 91-22-66455645
Email: clinical.trials@sparcmail.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.